BU's Covid tinkering & why it's hard to take drugs off the market – STAT

Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
By Damian Garde , Allison DeAngelis and Adam Feuerstein Oct. 20, 2022
What happens when approved drugs turn out not to work? Is it OK to make SARS-CoV-2 hybrids? And are British tabloids reliable sources of science news?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Lawyer and bioethicist ​​Holly Fernandez Lynch joins us to explain a watershed test of the FDA’s authority to revoke drug approvals. And STAT’s Helen Branswell calls in to discuss the headline-grabbing research at Boston University involving a lab-developed version of the virus that causes Covid-19.

For more on what we cover, here’s the news on the FDA; here’s the latest on the BU research; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.
advertisement
Be sure to sign up on Apple Podcasts, Spotify, StitcherGoogle Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
National Biotech Reporter
Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast.
Biotech Startups and Venture Capital Reporter
Allison is a biotech reporter at STAT, covering biopharma startups and venture capital.
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.




This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need

source

Add a Comment

Your email address will not be published. Required fields are marked *